Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • In Brief
  • Published:

Multiple sclerosis

MS drug beneficial in an underrepresented group

Nature Reviews Neurology (2025)Cite this article

Real-world data indicate that ocrelizumab is safe and effective in Latino people with multiple sclerosis (MS), according to a recent report. In a prospective observational study, a total of 305 people with relapsing–remitting MS, primary progressive MS or secondary progressive MS received ocrelizumab during a median follow-up period of 29.5 months. Only one person experienced a relapse, and disability worsened in only 12.4% of participants overall, with the highest risk in the group with secondary progressive MS. The findings provide evidence for efficacy and safety in a group that has been underrepresented in clinical trials of the drug.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

Original article

Download references

Author information

Authors and Affiliations

  1. Nature Reviews Neurology http://www.nature.com/nrneurol/

    Ian Fyfe

Authors
  1. Ian Fyfe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ian Fyfe.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fyfe, I. MS drug beneficial in an underrepresented group. Nat Rev Neurol (2025). https://doi.org/10.1038/s41582-025-01060-3

Download citation

  • Published:

  • DOI: https://doi.org/10.1038/s41582-025-01060-3

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing